Immunohistochemical detection of PD-L1 in small cell lung cancer and its prognostic values.
[OBJECTIVE] The molecule known as Programmed death-ligand 1 (PD-L1) exerts an inhibitory effect on immune system reactions and promotes cancer progression.
- p-value P<0.01
- p-value P<0.05
- HR 2.45
APA
Ma X, Gu J (2026). Immunohistochemical detection of PD-L1 in small cell lung cancer and its prognostic values.. American journal of translational research, 18(1), 788-796. https://doi.org/10.62347/OZEK2695
MLA
Ma X, et al.. "Immunohistochemical detection of PD-L1 in small cell lung cancer and its prognostic values.." American journal of translational research, vol. 18, no. 1, 2026, pp. 788-796.
PMID
41676289
Abstract
[OBJECTIVE] The molecule known as Programmed death-ligand 1 (PD-L1) exerts an inhibitory effect on immune system reactions and promotes cancer progression. Its prognostic role in small cell lung cancer (SCLC) remains less defined than in non-small cell lung cancer. This study aimed to evaluate PD-L1 expression and its prognostic value in SCLC, comparing detection by immunohistochemistry (IHC) and reverse transcription quantitative polymerase chain reaction (RT-qPCR).
[METHODS] PD-L1 expression was assessed in paired tumor and non-tumor tissues from 66 SCLC patients using IHC and RT-qPCR. IHC positivity was defined as membrane staining in >5% of tumor cells. Associations with clinicopathological factors were examined by Fisher's exact test. Survival analysis employed Kaplan-Meier curves and log-rank tests. Univariate and multivariate Cox regression identified independent prognostic factors.
[RESULTS] IHC analysis showed PD-L1 positivity in 34/66 patients. RT-qPCR revealed significantly higher PD-L1 mRNA levels in tumor versus non-tumor tissues (P<0.01). Both IHC positivity and high mRNA levels were associated with larger tumor size, metastasis, and advanced clinical stage (all P<0.05), but not with age, gender, or smoking/drinking history. Patients with PD-L1-positive IHC staining or high PD-L1 mRNA exhibited significantly worse 5-year overall survival (P<0.05), with IHC showing stronger prognostic discrimination. Multivariate analysis confirmed IHC positivity (HR=2.45, P=0.004) and high mRNA level (HR=2.12, P=0.012) as independent predictors of poor survival.
[CONCLUSION] PD-L1 expression is associated with aggressive clinicopathological features and independently predicts poor survival in SCLC. IHC appears to be a more sensitive detection method than RT-qPCR for prognostic assessment.
[METHODS] PD-L1 expression was assessed in paired tumor and non-tumor tissues from 66 SCLC patients using IHC and RT-qPCR. IHC positivity was defined as membrane staining in >5% of tumor cells. Associations with clinicopathological factors were examined by Fisher's exact test. Survival analysis employed Kaplan-Meier curves and log-rank tests. Univariate and multivariate Cox regression identified independent prognostic factors.
[RESULTS] IHC analysis showed PD-L1 positivity in 34/66 patients. RT-qPCR revealed significantly higher PD-L1 mRNA levels in tumor versus non-tumor tissues (P<0.01). Both IHC positivity and high mRNA levels were associated with larger tumor size, metastasis, and advanced clinical stage (all P<0.05), but not with age, gender, or smoking/drinking history. Patients with PD-L1-positive IHC staining or high PD-L1 mRNA exhibited significantly worse 5-year overall survival (P<0.05), with IHC showing stronger prognostic discrimination. Multivariate analysis confirmed IHC positivity (HR=2.45, P=0.004) and high mRNA level (HR=2.12, P=0.012) as independent predictors of poor survival.
[CONCLUSION] PD-L1 expression is associated with aggressive clinicopathological features and independently predicts poor survival in SCLC. IHC appears to be a more sensitive detection method than RT-qPCR for prognostic assessment.
같은 제1저자의 인용 많은 논문 (5)
- The tumor microenvironment as a key regulator of radiotherapy response.
- Genetic disruption of mitochondrial dynamics and stasis leads to liver injury and tumorigenesis.
- Mitochondrial dynamics, quality control, and mtDNA in alcohol-associated liver disease and liver cancer.
- ALKBH5 facilitates acute myeloid leukemia development and immune escape via PD-L1 regulation.
- First-line PD-1 inhibitor plus chemotherapy improves outcomes in advanced gastric cancer and correlates with specific biomarkers in a real-world cohort.